Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer

The identification of tumor “oncogenic drivers” and the subsequent development of targeted therapy represented a milestone in the treatment of lung cancer over the last years. Tumor genotyping has been incorporated into therapeutic decision making of advanced non-small cell lung cancer (NSCLC) since...

Descripción completa

Detalles Bibliográficos
Autores principales: Listì, Angela, Barraco, Nadia, Bono, Marco, Insalaco, Lavinia, Castellana, Luisa, Cutaia, Sofia, Ricciardi, Maria Rita, Gristina, Valerio, Bronte, Enrico, Pantuso, Gianni, Passiglia, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799193/
https://www.ncbi.nlm.nih.gov/pubmed/35117064
http://dx.doi.org/10.21037/tcr.2018.10.04

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799193/
https://www.ncbi.nlm.nih.gov/pubmed/35117064
http://dx.doi.org/10.21037/tcr.2018.10.04

Ejemplares similares